ResearcherEngeneic (Australia)Active in the last 2 years

Himanshu N. Brahmbhatt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4796-9890; OpenAlex author ID A5087036316. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper

Papers 2

Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate. Co-author DOI 10.1093/oncolo/oyae267 ↗
Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells. Last author DOI 10.1158/1078-0432.ccr-23-1821 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Katayoun Moini · 1 shared paper, 2025 · strength 0.27
- Paper Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate. DOI 10.1093/oncolo/oyae267 ↗
Patrick Soon‐Shiong · 1 shared paper, 2025 · strength 0.27
- Paper Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate. DOI 10.1093/oncolo/oyae267 ↗
Tara Elisabeth Seery · 1 shared paper, 2025 · strength 0.27
- Paper Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate. DOI 10.1093/oncolo/oyae267 ↗
Vinod Ganju · 1 shared paper, 2024 · strength 0.23
- Paper Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nano… DOI 10.1158/1078-0432.ccr-23-1821 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.